- NCIt
- C40022
Loading cancer entity…
Loading cancer entity…
Clinical trials
294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 58 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04019288 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| terminated |
| Phase 1 / Phase 2 |
| 12 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 11, 2025 |
| clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 46 | University of PennsylvaniaOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | terminated | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT01952249 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian(SIERRA) | terminated | Phase 1 | 20 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Sep 22, 2025source: clinicaltrials